专利检索 ap:("SILLAJEN BIOTHERAPEUTICS, INC." OR "SILLAJEN, INC.") AND inv:"Tae-Ho Hwang" 第 1 页

1.

发明授权
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus 有权

公开(公告)号：US10434169B2

公开(公告)日：2019-10-08

申请号：US15892247

申请日：2018-02-08

申请人： SILLAJEN BIOTHERAPEUTICS, INC. , SILLAJEN, INC.

发明人： David Kirn , John Bell , Caroline Breitbach , Anne Moon , Tae-Ho Hwang , Yu Kyoung Lee , Mi-kyung Kim

IPC分类号： A61K39/285 , A61K39/00 , C07K16/30 , A61K35/76 , A61K35/761 , A61K35/763 , A61K35/768 , A61K35/26 , A61K39/12 , A61K39/125 , A61K39/145 , A61K39/165 , A61K39/17 , A61K39/205 , A61K39/235 , A61K39/245 , A61K39/395 , A61K45/06 , C07K16/18 , C12N7/00 , G01N33/574

摘要： The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.